Recent 8-K filings for QNCX

• May 18, 2026 20:20 UTC other_material materiality 0.75 positive item 7.01item 9.01

  Quince reports positive Phase 2a LAM-001 data in PH-ILD; 6MWD +67.4m, PVR -33.9%

  Phase 2a open-label trial in PH-ILD (n=4 evaluable) on stable treprostinil showed 6MWD increase of 67.4 meters and PVR reduction of 33.9% at 24 weeks.

• May 18, 2026 13:33 UTC m_and_a materiality 1.00 neutral item 1.01item 5.03item 2.01item 3.02item 5.02item 7.01item 9.01

  Quince acquires Orphai in reverse merger; raises $115M PIPE; appoints Dr. Roberts

  Acquisition closed May 18; Quince issued 3.26M shares and 67K Series C Preferred to Orphai holders.

• Mar 30, 2026 23:59 UTC debt materiality 0.75 positive item 1.02item 7.01item 9.01

  Quince settles $16.4M EIB debt for $5.5M, eliminates debt overhang

  Paid $5.5M to settle ~$16.4M in EIB debt obligations, a discount of roughly $10.9M.

• Mar 20, 2026 23:59 UTC other_material materiality 0.75 negative item 3.01

  Quince Therapeutics receives two Nasdaq deficiency notices with 180-day cure periods

  Bid Price Notice: common stock closing bid below $1.00 for 30 consecutive business days; cure by Sept 14, 2026.

• Feb 12, 2026 23:59 UTC other_material materiality 0.90 negative item 2.02item 8.01

  Quince Therapeutics reports $5.8M cash, $16.4M debt; engages LifeSci Capital for reverse merger

  As of Dec 31, 2025, cash and short-term investments total $17.7M; EIB Loan outstanding $16.4M.

• Feb 02, 2026 23:59 UTC leadership materiality 0.70 negative item 5.02

  Five directors resign from Quince Therapeutics board effective immediately

  Directors Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray resigned on Jan 30, 2026.

• Jan 29, 2026 23:59 UTC other_material materiality 0.85 negative item 9.01

  Quince Therapeutics Phase 3 NEAT trial misses primary endpoint; eDSP development halted

  Primary endpoint RmICARS p=0.0851; mean change from baseline -1.30 vs placebo.

• Nov 12, 2025 23:59 UTC earnings materiality 0.70 positive item 2.02item 9.01

  Quince Therapeutics Q3 net loss $13.3M; Phase 3 NEAT trial on track for Q1 2026 data

  Cash, cash equivalents, and short-term investments of $26.3M; runway expected through Q2 2026.

• Aug 11, 2025 23:59 UTC earnings materiality 0.70 neutral item 2.02item 9.01

  Quince completes Phase 3 NEAT enrollment; Q2 net loss $16.1M

  Pivotal Phase 3 NEAT trial enrollment completed with 105 participants; topline results expected Q1 2026.

• Jul 16, 2025 23:59 UTC other_material materiality 0.70 positive item 7.01item 8.01item 9.01

  Quince completes Phase 3 NEAT enrollment with 105 patients; topline results Q1 2026

  Enrolled 105 participants total; 83 in primary analysis (ages 6-9), 22 aged 10+.

• Jun 13, 2025 23:59 UTC other_material materiality 0.65 neutral item 1.01item 3.02item 9.01

  Quince raises $11.5M in private placement of stock and warrants; management participates

  Sold 6,671,928 shares, 2M pre-funded warrants, and 8,671,928 common warrants for $11.5M gross proceeds.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.70 · Most common event other_material

4 positive 5 negative 8 neutral

source · QNCX on sec.gov